A prospective randomised study of CSA monotherapy versus CSA plus mycophenolate mofetil in cadaveric renal transplant recipients

Transplantation Proceedings

Volumn 30, Issue 8, 1998, Pages 4098-

  Sells, R A ^a   Bakran, A ^a   Brown, M W ^a   Grinyo, J ^a   Hammad, A ^a   Hyatt, D ^a   Owens, G ^a  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID;

CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEPHROTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

CADAVER; CREATININE; CYCLOSPORINE; DRUG THERAPY, COMBINATION; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; SURVIVAL RATE; TISSUE DONORS;

EID: 0032440513     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0041-1345(98)01356-6     Document Type: Conference Paper

References (3)

1. 1. Sells RA: Royal Society of Medicine Round Table Series 34:333, 1994
2. 2. Sells RA: Transplant Rev 11:111, 1997
3. 3. European Mycophenolate Mofetil Co-operative Study Group: Lancet 345:1321, 1995